STOCK TITAN

Recursion Pharmaceuticals (RXRX) EPS by Year

RXRX NASDAQ

Recursion Pharmaceuticals, Inc. lost $1.44 per diluted share in fiscal year 2025. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $0.86 per diluted share. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Recursion Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$1.44
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RXRX EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
EPS (Diluted)-$0.86-$1.44-$1.69n/m-$1.58n/m-$1.36n/m-$1.49-$3.99n/m-$2.87

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

RXRX EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
EPS (Diluted)-$0.22n/m-$0.25n/m-$0.22n/m-$0.17-$0.36-$0.41-$0.50-$0.57n/m-$0.34n/m-$0.40n/m-$0.39n/m-$0.42n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Recursion Pharmaceuticals, Inc. financials

Frequently Asked Questions

Recursion Pharmaceuticals, Inc. lost $1.44 per diluted share in fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) reported a loss of $0.86 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 7 fiscal years this page covers, Recursion Pharmaceuticals, Inc. (RXRX) diluted earnings per share went from -$2.87 in fiscal year 2019 to -$1.44 in fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) reported -$0.22 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Recursion Pharmaceuticals, Inc. (RXRX) reported on that line in every period on record.